Journal of Multiple Sclerosis

USA

Publications

• Research Article   
  A Retrospective Study of Utilization of Repository Corticotropin Injection (HP Acthar Gel) as Pretreatment for Alemtuzumab Infusion
  Author(s): Christen Kutz*
  
  Background: Alemtuzumab treatment of patients with MS is associated with cytokine release, resulting in infusion-associated reactions (IARs). Premedication with corticosteroids is typically administered to alleviate the risk of IARs, but steroid pretreatment is not feasible in some patients. This study investigated real-world experience using repository corticotropin injection (RCI) as a pretreatment for alemtuzumab infusion. Methods: A retrospective study of patients who were prescribed RCI as pretreatment for the prevention of alemtuzumab IARs was conducted using an electronic questionnaire. Data were de-identified at the time of collection. Results: Complete information on 175 patients was collected and analyzed. Data for alemtuzumab Course 1 infusions were available for 175 patients; 23 of these also had data availab.. View More»
  

  Abstract HTML PDF